Brought to you by 
TauRx raises $31.5mm in first tranche of $111.8mm venture financing; received all
15 Oct 2015
Executive Summary
Malaysian investment firm Genting Berhad’s Genting Management (Singapore) Pte. Ltd. has invested $31.5mm in TauRx Pharmaceuticals Ltd. (therapeutics and diagnostics for neurodegenerative diseases)--for a 5.6% stake--in the first tranche of a financing that could total $111.8mm, eventually providing Genting with a 20% holding to become the largest shareholder. The second tranche is expected by year end. Executives from Genting Berhad joined the company’s board.
Deal Industry
- Biotechnology
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
Deal Status
- Final
Deal Type
-
Financing
- Venture Financing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
TauRx raises $31.5mm in first tranche of $111.8mm venture financing; received all
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice